Despite an initial response, most patients with epithelial ovarian cancer will develop acquired resistance to platinum-based chemotherapy. Later-line options typically involve non-platinum-based chemotherapy with or without bevacizumab, although these usually provide only limited benefit. Now, data from the phase III MIRASOL trial demonstrate the activity of the antibody–drug conjugate mirvetuximab soravtansine in patients with folate-receptor-α (FRα)-high disease in this setting.

中文翻译：

---

米妥昔单抗索拉坦辛治疗铂类耐药上皮性卵巢癌优于化疗

尽管最初有反应，但大多数上皮性卵巢癌患者会对铂类化疗产生获得性耐药。后期选择通常涉及非铂类化疗，联合或不联合贝伐珠单抗，尽管这些通常只能提供有限的益处。现在，III 期 MIRASOL 试验的数据证明了抗体药物偶联物 mirvetuximab soravtansine 在这种情况下叶酸受体 α (FRα) 高疾病患者中的活性。